196 related articles for article (PubMed ID: 22291034)
1. Epstein-Barr virus neutralizing antibody levels and risk of multiple sclerosis.
Simon KC; O'Reilly EJ; Munger KL; Finerty S; Morgan AJ; Ascherio A
Mult Scler; 2012 Aug; 18(8):1185-7. PubMed ID: 22291034
[TBL] [Abstract][Full Text] [Related]
2. Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis.
De Jager PL; Simon KC; Munger KL; Rioux JD; Hafler DA; Ascherio A
Neurology; 2008 Mar; 70(13 Pt 2):1113-8. PubMed ID: 18272866
[TBL] [Abstract][Full Text] [Related]
3. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
Levin LI; Munger KL; Rubertone MV; Peck CA; Lennette ET; Spiegelman D; Ascherio A
JAMA; 2005 May; 293(20):2496-500. PubMed ID: 15914750
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study.
Ascherio A; Munger KL; Lennette ET; Spiegelman D; Hernán MA; Olek MJ; Hankinson SE; Hunter DJ
JAMA; 2001 Dec; 286(24):3083-8. PubMed ID: 11754673
[TBL] [Abstract][Full Text] [Related]
5. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.
Farrell RA; Antony D; Wall GR; Clark DA; Fisniku L; Swanton J; Khaleeli Z; Schmierer K; Miller DH; Giovannoni G
Neurology; 2009 Jul; 73(1):32-8. PubMed ID: 19458321
[TBL] [Abstract][Full Text] [Related]
6. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus antibodies and vitamin D in prospective multiple sclerosis biobank samples.
Salzer J; Nyström M; Hallmans G; Stenlund H; Wadell G; Sundström P
Mult Scler; 2013 Oct; 19(12):1587-91. PubMed ID: 23549431
[TBL] [Abstract][Full Text] [Related]
8. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel.
Munger KL; Levin LI; O'Reilly EJ; Falk KI; Ascherio A
Mult Scler; 2011 Oct; 17(10):1185-93. PubMed ID: 21685232
[TBL] [Abstract][Full Text] [Related]
9. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
Perez EM; Foley J; Tison T; Silva R; Ogembo JG
Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up.
DeLorenze GN; Munger KL; Lennette ET; Orentreich N; Vogelman JH; Ascherio A
Arch Neurol; 2006 Jun; 63(6):839-44. PubMed ID: 16606758
[TBL] [Abstract][Full Text] [Related]
11. Multiple sclerosis and Epstein-Barr virus.
Levin LI; Munger KL; Rubertone MV; Peck CA; Lennette ET; Spiegelman D; Ascherio A
JAMA; 2003 Mar; 289(12):1533-6. PubMed ID: 12672770
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus neutralizing and early antigen antibodies in multiple sclerosis.
Lindsey JW; Hatfield LM; Vu T
Eur J Neurol; 2010 Oct; 17(10):1263-9. PubMed ID: 20402753
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis: the elevated antibody response to Epstein-Barr virus primarily targets, but is not confined to, the glycine-alanine repeat of Epstein-Barr nuclear antigen-1.
Ruprecht K; Wunderlich B; Gieß R; Meyer P; Loebel M; Lenz K; Hofmann J; Rosche B; Wengert O; Paul F; Reimer U; Scheibenbogen C
J Neuroimmunol; 2014 Jul; 272(1-2):56-61. PubMed ID: 24798244
[TBL] [Abstract][Full Text] [Related]
14. Association of Epstein-Barr virus infection with multiple sclerosis in India.
Pandit L; Malli C; D'Cunha A; Shetty R; Singhal B
J Neurol Sci; 2013 Feb; 325(1-2):86-9. PubMed ID: 23312038
[TBL] [Abstract][Full Text] [Related]
15. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
[TBL] [Abstract][Full Text] [Related]
16. Fine specificity of the antibody response to Epstein-Barr nuclear antigen-2 and other Epstein-Barr virus proteins in patients with clinically isolated syndrome: A peptide microarray-based case-control study.
Schlemm L; Giess RM; Rasche L; Pfuhl C; Wakonig K; Behrens JR; Scheibenbogen C; Bellmann-Strobl J; Paul F; Reimer U; Ruprecht K
J Neuroimmunol; 2016 Aug; 297():56-62. PubMed ID: 27397076
[TBL] [Abstract][Full Text] [Related]
17. The beneficial effects of vitamin D3 on reducing antibody titers against Epstein-Barr virus in multiple sclerosis patients.
Najafipoor A; Roghanian R; Zarkesh-Esfahani SH; Bouzari M; Etemadifar M
Cell Immunol; 2015 Mar; 294(1):9-12. PubMed ID: 25666504
[TBL] [Abstract][Full Text] [Related]
18. Antibodies from Multiple Sclerosis Brain Identified Epstein-Barr Virus Nuclear Antigen 1 & 2 Epitopes which Are Recognized by Oligoclonal Bands.
Wang Z; Kennedy PG; Dupree C; Wang M; Lee C; Pointon T; Langford TD; Graner MW; Yu X
J Neuroimmune Pharmacol; 2021 Sep; 16(3):567-580. PubMed ID: 32808238
[TBL] [Abstract][Full Text] [Related]
19. A prospective study of Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma.
Bertrand KA; Birmann BM; Chang ET; Spiegelman D; Aster JC; Zhang SM; Laden F
Blood; 2010 Nov; 116(18):3547-53. PubMed ID: 20647565
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus and disease activity in multiple sclerosis.
Buljevac D; van Doornum GJ; Flach HZ; Groen J; Osterhaus AD; Hop W; van Doorn PA; van der Meché FG; Hintzen RQ
J Neurol Neurosurg Psychiatry; 2005 Oct; 76(10):1377-81. PubMed ID: 16170080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
